Cyclacel Pharmaceuticals Alpha and Beta Analysis
| CYCCDelisted Stock | USD 6.37 0.39 5.77% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cyclacel Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cyclacel Pharmaceuticals over a specified time horizon. Remember, high Cyclacel Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cyclacel Pharmaceuticals' market risk premium analysis include:
Beta 0.0176 | Alpha 3.21 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cyclacel |
Cyclacel Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cyclacel Pharmaceuticals market risk premium is the additional return an investor will receive from holding Cyclacel Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cyclacel Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cyclacel Pharmaceuticals' performance over market.| α | 3.21 | β | 0.02 |
Cyclacel Pharmaceuticals Fundamentals Vs Peers
Comparing Cyclacel Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cyclacel Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Cyclacel Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cyclacel Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cyclacel Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cyclacel Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cyclacel Pharmaceuticals to competition |
| Fundamentals | Cyclacel Pharmaceuticals | Peer Average |
| Return On Equity | -2.77 | -0.31 |
| Return On Asset | -1.03 | -0.14 |
| Current Valuation | 10.9 M | 16.62 B |
| Shares Outstanding | 2.24 M | 571.82 M |
| Shares Owned By Insiders | 80.14 % | 10.09 % |
| Shares Owned By Institutions | 0.79 % | 39.21 % |
| Number Of Shares Shorted | 96.28 K | 4.71 M |
Cyclacel Pharmaceuticals Opportunities
Cyclacel Pharmaceuticals Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | 12 Health Care Stocks Moving In Fridays After-Market Session | 07/18/2025 |
2 | Is it the right time to buy Cyclacel Pharmaceuticals Inc. stock - Stock Strategy Recommendation For Every Investor - jammulinksnews.com | 07/31/2025 |
3 | Cyclacel Pharmaceuticals Stock Up 34.6 percent In Massive After-Hours Rally | 08/05/2025 |
4 | Cyclacel Pharmaceuticals GAAP EPS of -0.98 | 08/13/2025 |
5 | Can Traders Expect Breakout From Cyclacel Pharmaceuticals Inc. This Week - 2025 Retail Activity Real-Time Chart Pattern Alerts - thegnnews.com | 08/22/2025 |
6 | Is Cyclacel Pharmaceuticals Inc. stock poised for growth - Market Movement Recap AI Based Buy and Sell Signals - Newser | 08/25/2025 |
7 | Has Cyclacel Pharmaceuticals Inc. formed a bullish divergence - Market Movement Recap Consistent Profit Trading Strategies - Newser | 08/28/2025 |
8 | What are Cyclacel Pharmaceuticals Inc.s earnings expectations - Market Movers Expert Approved Trade Ideas - khodrobank.com | 09/03/2025 |
9 | Major Shareholder Cashes Out Big on Cyclacel Pharmaceuticals - TipRanks | 09/10/2025 |
About Cyclacel Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cyclacel or other delisted stocks. Alpha measures the amount that position in Cyclacel Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Cyclacel Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Cyclacel Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyclacel Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cyclacel Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cyclacel Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Cyclacel Pharmaceuticals' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cyclacel Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Cyclacel Stock
If you are still planning to invest in Cyclacel Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclacel Pharmaceuticals' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |